35th week of 2015 patent applcation highlights part 7 |
Patent application number | Title | Published |
20150238390 | DENTAL COMPOSITION - A dental cement hardened by a cement reaction involving the specific polymerizable polyacidic polymer and optionally additional crosslinkable groups, has reduced shrinkage and improved mechanical properties, in particular with regard to flexural strength and fracture toughness. Moreover, the specific polymerizable polyacidic polymer of the present invention contains a high number of acidic groups which is not reduced by the presence of polymerizable moieties, whereby water solubility of the uncured polymer is not impaired by the presence of the polymerizable moieties. | 2015-08-27 |
20150238391 | BLEACHING AGENTS - Solid cosmetic agents, which contain a) at least one liquid fatty substance a), b) at least one powdery organic carrier material b), c) at least one cosmetic active agent c) that is different from a) and b), characterized in that the fatty substance a) and the powdery organic carrier material b) are in the form of a powdery aggregate A, the proportion by weight of the fatty substance a) relative to the total weight of this powdery aggregate A being higher than the proportion by weight of the fatty substance a) relative to the total weight of the solid cosmetic agent, are characterized by an above-average care effect in the bleaching of keratinic fibers. | 2015-08-27 |
20150238392 | COSMETIC COMPOSITION FOR COATING KERATIN FIBRES - The present invention relates to an emulsion-type cosmetic composition for coating keratin fibres, comprising: —an aqueous phase, —particles comprising: * at least one hard wax, preferentially in the form of an aqueous dispersion, having a melting point ranging from 65 to 120° C., the hard wax(es) being present at a total content greater than or equal to 10% by weight relative to the total weight of the composition, * preferably at least one aqueous dispersion of particles of at least one film-forming polymer, the film forming polymer(s) preferably being present at a dry matter content greater than or equal to 10% by weight relative to the total weight of the composition, —at least one particular emulsifying system capable of dispersing at least the hard wax(es), the total content of hard wax(es) and optionally of additional wax(es) and the total content of emulsifying system being such that the weight ratio of the hard wax(es) plus additional wax(es) to the emulsifying system is less than or equal to 1.75, the composition comprising a solids content greater than or equal to 42%. The present invention also relates to a method for coating keratin fibres, to a method for preparing a cosmetic composition for coating keratin fibres, to a cosmetic composition for coating keratin fibres which is obtained by means of said production method, and also to a particular use. | 2015-08-27 |
20150238393 | COSMETIC COMPOSITION FOR COATING KERATIN FIBRES - The present invention relates to an emulsion-type cosmetic composition for coating keratin fibres, comprising:—an aqueous phaserepresenting from 30% to 80% by weight, preferably from 40% to 70% by weight, relative to the total weight of the composition,—particles comprising at least one hard wax, preferentially in the form of an aqueous dispersion, having a melting point ranging from 65 to 120° C., the hard wax(es) being present at a total content greater than or equal to 10% by weight relative to the total weight of the composition,—at least one emulsifying system capable of dispersing at least the hard wax(es), comprising a non-ionic surfactant with an HLB value at 25° C. greater than or equal to 8, preferably greater than or equal to 10, comprising a monoester of a C | 2015-08-27 |
20150238394 | Triggerable Compositions For Two-Stage, Controlled Release of Proactive Chemistry Using Aldehydes - A triggerable composition for two-stage, controlled release of a functional active chemical includes an aldehyde-based functional active incorporated in an organic salt-based acetal that releases the functional active through a hydrolysis reaction upon contact with an aqueous medium, and an encapsulation material for encapsulating the organic salt-based acetal, the encapsulation material triggerable to release or expose the organic salt-based acetal upon the occurrence of an environmental stimulus such as a pH change. The triggerable composition can be included in an absorbent article having at least one absorbent layer or in a viscous liquid such as a lotion, cream, or medicament. | 2015-08-27 |
20150238395 | Toothpaste Composition - Described herein are toothpaste compositions comprising an orally acceptable vehicle; calcium carbonate; and a binder system comprising guar gum and at least one cellulose polymer. | 2015-08-27 |
20150238396 | Method for Oxygen Treatment of Intact Skin - Oxygen therapy for healthy or inflamed but intact skin involves placing an oxygen-generating dressing onto the skin to be treated, the oxygen-generating bandage being a one-time use dressing capable of generating oxygen for only a short period of time, not to exceed about 4 hours. | 2015-08-27 |
20150238397 | PEROXIDE GEL COMPOSITIONS - The present invention is a formable dental treatment tray utilizing poly(2-ethyl-2-oxazoline) and a gelatinous active. Blending of the active is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with an active ingredient, such as a peroxide like hydrogen peroxide, carbamide peroxide, sodium perborate, or sodium percarbonate, usually also with water or an appropriate organic solvent. Peroxide concentrations in these new gels can reach a 30% concentration of hydrogen peroxide while maintaining a shelf life of six months at room temperature without developing peroxide decomposition. The gels are applied to an appropriate backing and dried to a gelatinous state. In use, the active is hydrated and regains adhesiveness. Then the tray is pressed and formed around a user's dental arch to form the customizable tray. Multiple active ingredients may be used, with or without peroxide, for accomplishing desired treatment regimens. | 2015-08-27 |
20150238398 | AQUEOUS OXIDIZING COMPOSITION - Present invention relates to an aqueous oxidizing composition with improved peroxide stability. The aqueous compositions of the present invention comprises at least oxidizing agent, at least one magnesium salt and have a pH between 1 and 5. | 2015-08-27 |
20150238399 | TOOTH WHITENING COMPOSITION - The present invention relates to a teeth whitening composition comprising 0.1 wt. % to 6 wt. % hydrogen peroxide, based on the total weight of the composition, and a nanohydroxy apatite having an average diameter of 0.1 to 20 nm. The present invention further relates to a teeth whitening kit comprising two separated components, wherein the first component comprises 0.1 wt. % to 6 wt. % hydrogen peroxide, based on the total weight of the first component, and the second component comprises a nanohydroxy apatite having an average diameter of 0.1 to 20 nm. The present invention also relates to a process for preparing a teeth whitening composition and to a dispenser for the teeth whitening kit. | 2015-08-27 |
20150238400 | ANTIPERSPIRANT AEROSOL COMPOSITION - According to a first aspect, antiperspirant aerosol compositions are disclosed comprising antiperspirant active particulates, a propellant and at least 5% by weight of the entire antiperspirant aerosol composition of a silicone component, wherein (a) the antiperspirant active particulates are the only particulates in the antiperspirant aerosol composition; (b) the silicone component comprises one or more silicones and the or each silicone is a non-volatile silicone. According to a second aspect, packaged antiperspirant aerosol compositions according to the first aspect are disclosed. | 2015-08-27 |
20150238401 | PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE - Provided is a compound that exhibits an excellent melanogenesis-inhibiting effect (skin-lightening effect), exhibits an excellent antimicrobial effect, excels in terms of temporal stability and the like, and is suitable for use as an ingredient of a cosmetic. Said compound is a propyl-phenyl-ether derivative compound comprising a propyl group that has a substituent such as a hydroxyl group and is bound to the hydroxyl group of a phenol group that has a substituent such as a tert-butyl group. A melanogenesis inhibitor, skin-lightening agent, and antimicrobial agent containing the aforementioned compound as an active ingredient are also provided, as is a cosmetic characterized by containing said compound. | 2015-08-27 |
20150238402 | PROCESS - Process for making a conditioning gel phase comprising: forming an aqueous isotropic solution of cationic surfactant; mixing the aqueous isotropic solution of cationic surfactant withmoltenfatty alcohol wherein the temperature during mixing the fatty alcohol with the isotropic cationic surfactant solution is maintained from 55° C. to 65° C. | 2015-08-27 |
20150238403 | LOW VISCOUS COSMETIC COMPOSITION USING A NATURAL EMULSIFYING AGENT - The present invention relates to a low-viscosity cosmetic composition using a natural emulsifying agent. More specifically, the present invention relates to a cosmetic composition using a naturally derived saccharide-based surfactant in place of a chemical surfactant and realizing a low-viscosity formulation to offer safety to the skin, feel good on the skin with fast absorption, give stability to the formulation and add luster to the skin in an effective manner. | 2015-08-27 |
20150238404 | Transglutaminase Activator - A transglutaminase activator containing at least one kind selected from the group consisting of an extract from | 2015-08-27 |
20150238405 | COSMETIC COMPOSITION - Disclosed is a cosmetic composition comprising particles dispersed in a cosmetically acceptable carrier, wherein the particles comprise redox dye and reducing agent. | 2015-08-27 |
20150238406 | FINASTERIDE POLYMERIC NANOPARTICLE, AQUEOUS SUSPENSION CONTAINING THE SAME, COMPOSITION FOR THE TREATMENT OF ALOPECIA, PROCESS OF PREPARATION OF SAID COMPOSITION, AND ITS USE - The present invention aims to provide a pharmaceutical composition for the treatment of alopecia, said composition comprising polymeric nanoparticles, preferably nanocapsules, containing finasteride, additives and a pharmaceutically acceptable carrier, as well as the use of the nanoparticles for preparing said composition for treating alopecia. The invention further includes an appropriate finasteride nanocapsule preparation process suitable for a composition for topical application for treating alopecia. | 2015-08-27 |
20150238407 | SURFACTANT AND SOLVENT-FREE HEAVY DUTY SKIN CLENSER - Disclosed herein are skin cleansing formulations for cleaning heavy duty oil/dirt from skin based on lipophilic particles such as particulate polymers of norbornene as a hydrophobic stain-removing agent for the replacement of all or part of the surfactants and lipophilic solvents normally involved in greasy stain-removing heavy duty skin cleansers. | 2015-08-27 |
20150238408 | Ester Gels, Methods of Manufacture, and Uses Thereof - Gels of isopropyl esters of fatty alcohols that include a dimethyl/methylhydrogensiloxane copolymer, a silanol-terminated PDMS or an ethenyl-terminated PDMS, and a hydride functional siloxane. Also provided are methods for making the gels and articles containing them. | 2015-08-27 |
20150238409 | MULTI USE COSMETIC FORMULA - The invention relates to formulations that comprise non-irritating non-toxic compounds that may be applied to the skin for generally improvement of health and beauty. The formulations include core ingredients of minerals, oils, and emulsifiers. Additional ingredients may be added to provide a variety of formulations for skin hydration, softening, soothing, deodorizing, and cosmetic application. The formulations may be use as a carrier for cosmetics, fragrances, or therapeutic agents. | 2015-08-27 |
20150238410 | ULTRASOUND ANTI STRETCH MARK GEL COMPOSITION - An improved ultrasound imaging gel for topical use and a method for create such comprising: water, propylene glycol, glycerin, phenoxyethanol or Carbopol® 940 Polymer, perfumes and dyes combined with equisetum arvense, alchemilla vulgaris, and hedera helix. The improved ultrasound imaging gel may be dispensed from a bottle, where the bottle includes: a body portion, where the body portion includes a slight indenture at a top diameter; a nipple, where the nipple includes an opening for the dispensing of the gel through the opening; and a ribbed base surrounding the nipple. | 2015-08-27 |
20150238411 | COMPOSITION CONTAINING TEA WATER FOR SUPPRESSING AGING OF SKIN - The present invention discloses a composition for suppressing the aging of skin, which contains tea water derived from fresh tea leaves having inactivated enzymes. The composition containing tea water according to the present disclosure may inhibit the activities of matrix metalloproteinase (MMP) and elastase, stimulate the production of collagen by increasing its expression, suppress the formation of skin wrinkles, and reduce the formed skin wrinkles. Furthermore, it has an excellent effect of suppressing skin aging. | 2015-08-27 |
20150238412 | ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE PARTICLES USING A METERED DOSE INHALER - Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90<5.0 micron volumetric median diameter. | 2015-08-27 |
20150238413 | METHOD FOR MANUFACTURING TRANSDERMAL-ABSORPTION SHEET - A method is provided which enables a drug to be concentrated at needle-like protruding portions and which further allows transdermal-absorption sheets to be manufactured at high production efficiency. The method repeats a step of feeding a drug-containing solution from a liquid feeding apparatus to a mold and filling needle-like recessed portions with the drug-containing solution through a nozzle aligned over the needle-like recessed portions in a state where the nozzle and a front surface of the mold are brought into contact with each other, and a step of moving the liquid feeding apparatus relative to the mold in a state where the nozzle and the front surface of the mold are brought into contact with each other. Thus, the two-dimensionally arranged needle-like recessed portions are filled with the drug-containing solution. | 2015-08-27 |
20150238414 | Misoprostol Formulation - A method of reducing the likelihood of infection requiring use of antibiotics during or after induction of labour in a female, comprises administering intravaginally to the female an insert comprising a cross-linked polyurethane reaction product of a polyethylene glycol, a triol and a diisocyanate, the insert containing 200 μg misoprostol; the likelihood of infection being reduced in comparison to the administration of said insert containing 10 mg dinoprostone. | 2015-08-27 |
20150238415 | INTRAVAGINAL DEVICES FOR CONTROLLED DELIVERY OF LUBRICANTS - The present technology provides intravaginal devices designed to deliver lubricants to the vagina for a sustained period of time. The intravaginal devices include a first segment comprising an outer surface and a lumen containing a lubricant, wherein the first segment is configured to deliver the contents of the lumen to the outer surface, and the first segment comprises a polymer selected from the group consisting of a hydrophilic, semi-permeable elastomer and a hydrophobic elastomer. The lubricant may be an aqueous lubricant. The present technology further provides an intravaginal device including a solid first segment that includes a hydrophilic semi-permeable elastomer, an outer surface and an aqueous lubricant, wherein the first segment is configured to deliver the aqueous lubricant to the outer surface. | 2015-08-27 |
20150238416 | Pharmaceutical Composition - The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil. | 2015-08-27 |
20150238417 | INTEROMONE COMPOSITIONS AND THEIR USE TO MODIFY BEHAVIOR IN DIFFERENT VERTEBRATE SPECIES - A composition comprising an interomone is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the interomone is a naturally occurring pheromone. | 2015-08-27 |
20150238418 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 2015-08-27 |
20150238419 | PARTIALLY ABSORBABLE FIBER-REINFORCED COMPOSITES FOR CONTROLLED DRUG DELIVERY - This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment. | 2015-08-27 |
20150238420 | NALOXONE MONO PREPARATION AND MULTILAYER TABLET - The present invention relates to a solid oral pharmaceutical composition comprising naloxone, or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. In order to provide a composition that is suitable for an administration period of at least twelve-hours for the treatment of opioid-induced constipation, it is proposed that the composition should have an in vitro release rate of the active substance measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 500 ml 0.1 N hydrochloric acid at 37° C., of 0% to 75% in 2 h, of 3% to 95% in 4 h, of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to 100% in 24 h, and of more than 80% in 36 h, wherein the composition has a IC | 2015-08-27 |
20150238421 | Bilayer Tablet Formulations - The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. | 2015-08-27 |
20150238422 | TAMPER-RESISTANT DOSAGE FORM COMPRISING PHARMACOLOGICALLY ACTIVE COMPOUND AND ANIONIC POLYMER - The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N and comprising a pharmacologically active compound, an anionic polymer bearing carboxylic groups, wherein the content of the anionic polymer is ≧20 wt.-%, based on the total weight of the pharmaceutical dosage form, and a nonionic surfactant. | 2015-08-27 |
20150238424 | DISINTEGRATING PARTICLE COMPOSITION CONTAINING ACID-TYPE CARBOXYMETHYLCELLULOSE AND CRYSTALLINE CELLULOSE, AND ORALLY DISINTEGRATING TABLET CONTAINING SAID COMPOSITION - An object of the present application is to provide an orally-disintegrating tablet having excellent tablet hardness and disintegrability, and including a disintegrative particulate composition. This invention relates to a disintegrative particulate composition comprising the four components consisting of a first disintegrator component of an acid-type carboxymethylcellulose, a second disintegrator component other than the acid-type carboxymethylcellulose, an excipient of a sugar or sugar alcohol, and crystalline cellulose; and to an orally-disintegrating tablet, including the disintegrative particulate composition and a medicinal ingredient. | 2015-08-27 |
20150238425 | MINI-TABLETS - The present invention relates to a composition comprising a first granule with an antibiotic and a second granule with a β-lactamase inhibitor wherein at least one of the granules is a mini-tablet (a particle with defined dimensions), a composition contained in a sachet, pharmaceutical compositions comprising mini-tablets, the use of mini-tablets and a process for the preparation of mini-tablets. | 2015-08-27 |
20150238426 | GRANULAR MATERIAL FOR ORALLY FAST DISINTEGRATING TABLETS - The use of a granular material which is for orally fast disintegrating tablets and comprises at least one kind of water soluble polymer and tannic acid allows production of tablets that can be produced by a simple process with simple production equipment, disintegrate fast in the mouth, and have a proper level of moldability for practical use. The at least one kind of water soluble polymer is preferably selected from, the group consisting of povidone, hydroxypropyl cellulose, pallulan, a polyvinyl alcohol-polyethylene glycol graft copolymer and copolyvidone. | 2015-08-27 |
20150238427 | METHOD AND APPARATUS FOR DRY GRANULATION - The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules. | 2015-08-27 |
20150238428 | Systems and Methods for Increasing Stability of Dronabinol Compositions - Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability. | 2015-08-27 |
20150238429 | SOFT ELASTIC CAPSULES CONTAINING TABLETS AND LIQUID OR SEMISOLID FILLS AND METHODS FOR THEIR MANUFACTURE - Disclosed herein is a soft elastic capsule that includes an acid resistant, capsule shell that defines an encapsulated space having a predetermined volume, a liquid or semisolid fill comprising a first active ingredient located within the encapsulated space, and a first compressed tablet a having a minimal dimension of 2 mm, being located within the encapsulated space, unanchored to the capsule shell, and surrounded by the fill, said tablet comprising a second active ingredient that is substantially insoluble in the fill. A method of manufacturing a soft elastic capsule is also disclosed. | 2015-08-27 |
20150238430 | PHARMACEUTICAL COMPOSITION - A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life. | 2015-08-27 |
20150238431 | ICAM-1 TARGETING ELPS - Provided herein are therapeutic agents comprising an elastin-like peptide (ELP) component and a ligand that specifically targets and binds an ICAM-1 receptor. In one aspect, the ELP comprises, or alternatively consists essentially of, or yet further consists of one or more sequence(s) designated S48I48 and/or mICMA-1 SI and/or hICAM-1 S1 or biological equivalents thereof. In a further aspect, the ELP/ligand composition further comprises a therapeutic agent. In one aspect, the therapeutic agent is specific to the treatment or amelioration of symptoms associated with autoimmune disorders such as SjS. | 2015-08-27 |
20150238432 | Synthesis Of Oxygen Carrying, Turbulence Resistant, High Density Submicron Particulates - An artificial oxygen carrier (AOC) for use as a blood substitute in the body. A first gas permeable shell encloses an oxygen carrying agent. The first gas-permeable shell has a second oxygen carrying agent surrounding it, and there is a second gas-permeable shell enclosing the second agent. The concentric shells are not subject to turbulent breakup, or chemical decomposition, and do not release the oxygen carrying agents into the blood. | 2015-08-27 |
20150238433 | Design and Manufacture of Nonelectronic, Active-Infusion Patch and Device for Transdermal Delivery Across Skin - Transdermal patches and devices for delivery of therapeutic drug and/or cosmetic formulations through an intact or porated skin barrier are described. Active-infusion delivers controlled dosing over a period of time to provide long-term efficacy. Methods and devices for preparing active-infusion patches for controlled dose delivery by nonelectronic means and methods of skin poration that is safe and painless are described. | 2015-08-27 |
20150238434 | TRANSDERMAL ABSORPTION SHEET, AND MANUFACTURING METHOD FOR THE SAME - A transdermal absorption sheet and a manufacturing method for the transdermal absorption sheet includes a laminating step of forming a multilayer film with a viscosity difference by forming, on a support, a lower layer containing a first transdermal absorption material and an upper layer containing a drug and a second transdermal absorption material and having a lower viscosity than the lower layer, a filling step of filling needle-like recessed portions corresponding to inverted needle-like protruding portions with a solution of the transdermal absorption material by pressing a mold in which the needle-like recessed portions are arranged in a two-dimensional array, against a surface of the multilayer film supported by the support to allow the multilayer film to flow, a solidifying step of solidifying the multilayer film with the mold pressed against the surface of the multilayer film, and a peeling-off step of peeling the solidified multilayer film from the mold. | 2015-08-27 |
20150238435 | Oral Drug Devices and Drug Formulations - Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment, the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment. | 2015-08-27 |
20150238436 | SUPPORT BODY FOR TRANSDERMAL PATCH OR TRANSDERMAL PREPARATION, AND TRANSDERMAL PATCH AND TRANSDERMAL PREPARATION USING SAME - The present invention provides a patch or patch preparation in which the anchoring property of a pressure-sensitive adhesive layer to a support is improved with no adverse effects on its pressure-sensitive adhesive properties such as adhesion, pressure-sensitive adhesiveness, and a cohesive strength. A support of the present invention is for a patch or patches preparation, and comprises a base material containing a plastic film and an undercoat agent layer laminated on the base material. The undercoat layer contains porous inorganic particles having an average particle diameter of from 1 μm to 15 μm. A patch and patch preparation of the present invention comprises the support and a pressure-sensitive adhesive layer placed on one surface of the support to be adjacent to the undercoat agent layer. | 2015-08-27 |
20150238437 | TRANSDERMAL THERAPEUTIC SYSTEM WITH HIGH RATE OF UTILIZATION OF ACTIVE SUBSTANCE AND DOSING ACCURACY - A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer layer which is remote from the skin and is based on polyisobutylenes with a rate of application of at least 80 g/m | 2015-08-27 |
20150238438 | COMPOSITION COMPRISING SCIRPUSIN A AND SCIRPUSIN B AND ANTI-OBESITY POTENTIAL THEREOF - Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of | 2015-08-27 |
20150238439 | COMPOSITIONS AND METHODS FOR MODULATING DNMT1 INHIBITOR ACTIVITY - Some aspects of the invention include attenuating DNMT1 inhibitor activity in an animal comprising administering an antioxidant. Other aspects of the invention include methods comprising administering a composition comprising a DNMT1 inhibitor and an antioxidant. In some instances in the methods, the animal is undergoing a treatment for cancer. Additional aspects of the invention include compositions comprising a DNMT1 inhibitor and an antioxidant. | 2015-08-27 |
20150238440 | Acne Solution - A composition for the treatment of acne includes hydrolyzed | 2015-08-27 |
20150238441 | Modulation of Branched Amino Acid Concentrations to Treat Metabolic Diseases - The plasma concentration of at least one branched chain amino acid in a mammal in need of such reduction is reduced by administering an agent that increases the plasma concentration of large neutral amino acids. The invention also includes related compositions and methods. These methods and compositions can be used to treat insulin resistance, type 2 diabetes and metabolic syndrome. | 2015-08-27 |
20150238442 | Orally Dissolving Formulations of Memantine - Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease. | 2015-08-27 |
20150238443 | Method of Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release. | 2015-08-27 |
20150238444 | CHLORHEXIDINE GLUCONATE SOLUBILIZED IN A HYDROPHOBIC MONOACYLGLYCERIDE - Chlorhexidine gluconate solubilized in a hydrophobic monoacylglyceride is described. Compositions incorporating such materials, as well as methods of preparing such materials are also described. | 2015-08-27 |
20150238445 | COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS - The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity. | 2015-08-27 |
20150238446 | NEW TREATMENT OF FISH WITH A NANOSUS PENS ION OF LUFENURON OR HEXAFLUMURON - The present invention concerns a stable aqueous nanosuspension dosage formulation for injection to fish, comprising (i) an active ingredient which is lufenuron or hexaflumuron, each in form of particles having an effective average particle size of ≦1000 nm; (ii) one or more surface stabilizers selected from the group consisting of a surfactant and a polymer or a mixture thereof; and (iii) water. The nanosuspension formulations of the present invention are especially suited for the treatment of salmon and provide prolonged effective protection against sea lice at sea. | 2015-08-27 |
20150238447 | BETA-HYDROXY-BETA-METHYLBUTRYIC ACID-CONTAINING COMPOSITIONS AND USES THEREOF - Disclosed are compositions, such as liquid and solid nutritional compositions, that contain beta-hydroxy-beta-methylbutyric acid and optionally at least one protein, carbohydrate, fat, or a combination of protein, carbohydrate, and fat. Also disclosed are methods of using the compositions for improving physical endurance, locomotion, mobility and cognition in an individual, including a pediatric individual. | 2015-08-27 |
20150238448 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES - Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective α, β unsaturated aryl sulfone wherein the composition has a pH within the range of about 8 to about 9. | 2015-08-27 |
20150238449 | BENZENETRICARBOXYLIC ACID AND METHODS OF USE - Methods of treating or preventing cancer and/or a neurodegenerative disorder in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of 1,2,3-benzenetricarboxylic acid or a hydrate or pharmaceutically acceptable salt thereof. | 2015-08-27 |
20150238450 | ACTIVATION OF AMP-PROTEIN ACTIVATED KINASE BY OXALOACETATE COMPOUNDS - The present invention relates to oxaloacetate compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, Alzheimer's disease, and cancer. | 2015-08-27 |
20150238451 | Pharmaceutical compositions of diclofenac or salts thereof - The present invention refers to an improved pharmaceutical composition of diclofenac or pharmaceutically acceptable salt and pharmaceutically acceptable excipients wherein the composition is substantially free of solubilizing agents. By judicially using pharmaceutical excipients other than solubilizing agent, pharmaceutical composition of diclofenac or its salts with rapid and uniform gastrointestinal absorption of diclofenac can be achieved. The composition of the invention can also minimize the controllable side effects of diclofenac. | 2015-08-27 |
20150238452 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF MACULAR DEGENERATION DISORDERS - The present invention relates to combinations and methods for the treatment of macular degeneration disorders. More specifically, the present invention relates to novel combinatorial therapies of Age related Macular Degeneration based on baclofen and acamprosate combination. | 2015-08-27 |
20150238453 | BIO-AVAILABLE N-ACETYL CREATINE SPECIES AND COMPOSITIONS THEREOF - Creatine derivatives and compositions containing a [one or more?] bioactive form[s] of creatine. The new chemical entity comprises an acetyl creatine, N-acyl creatines, N,N-diacyl creatines or any N-acetyl creatine species with enhanced solubility and bioavailability. Also provided by this invention are various methods for providing several beneficial effects that comprise administering compositions comprising N-acetyl creatine, N-acyl creatines, N,N-diacyl creatines or any N-acetyl creatine species to a mammalian subject, either chronically or acutely. | 2015-08-27 |
20150238454 | USE OF SAPONIFIED TALL OIL FATTY ACID - The present invention relates to use of a tall oil fatty acid which is modified by saponification in the modulation of microbial population of the animal digestive tract. | 2015-08-27 |
20150238455 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2015-08-27 |
20150238456 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors. | 2015-08-27 |
20150238457 | SEMI-SOLID COMPOSITIONS AND PHARMACEUTICAL PRODUCTS - This invention relates to semi-solid compositions and semi-solid pharmaceutical products for use in the photodynamic treatment (PDT) of cancer, pre-cancerous conditions and non-cancerous conditions in the female reproductive system, the anus and the penis, preferably for use in PDT of endometrial, cervical, vulvar, vaginal, anal and penile dysplasia and HPV infections of the uterus, cervix, the vulva, the vagina, the anus and the penis. The semi-solid compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of PDT of cancer, pre-cancerous conditions and non-cancerous conditions in the female reproductive system, the anus and the penis, wherein said semi-solid compositions and pharmaceutical products are used. | 2015-08-27 |
20150238458 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. | 2015-08-27 |
20150238459 | COMPANION COSMETIC COMPOSITIONS - A composition includes dihydroquercetin, α-tocopherol and bisabolol. The use of the composition in a cosmetic method for limiting, alleviating and/or preventing cutaneous discomfort, especially cutaneous discomfort induced by a disease or induced by a therapy, a radiotherapy treatment and/or chemotherapy treatment, and the process of manufacturing the composition are also described. | 2015-08-27 |
20150238460 | Methods and Compositions For Treating Hepatocellular Carcinoma - Provided herein are methods of treating subjects having tumors. For example, the invention relates to a method for treating subjects having hepatocellular carcinoma by administering an effective amount of a therapeutic prodrug. | 2015-08-27 |
20150238461 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS - The present invention relates to the use of plant phenols, in particular, plant phenolic acids, like rosemarinic acid, ellagic acid, and chlorogenic acid in the treatment or prevention of eosinophilic esophagitis. | 2015-08-27 |
20150238462 | COMPOSITION COMPRISING PLANT PHENOLS FOR PREVENTING OR REDUCING TEWL AND ASSOCIATED DISORDERS AND DISEASES - The present invention relates to the use of plant phenols, in particular, plant phenolic acids, like rosemarinic acid, ellagic acid, and chlorogenic acid in preventing or reducing transepidermal water loss (TEWL) and associated disorders and diseases. | 2015-08-27 |
20150238463 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACID-RELATED GASTROINTESTINAL DISORDERS CONTAINING A DITHIOLANE COMPOUND AND A GASTRIC ACID SECRETION INHIBITOR - The present disclosure describes a treatment for acid related gastrointestinal disorders. The compounds described herein are known gastric acid secretion inhibitors in combination with alpha lipoic acid (ALA) or related compounds. ALA is not known as a treatment for acid related gastrointestinal disorders, however, ALA, when combined as described in the present disclosure with certain compounds used in the treatment of acid related gastrointestinal disorders, significantly improves existing treatments. | 2015-08-27 |
20150238464 | NUTRITIONAL COMPOSITION FOR IMPROVING HEART FAILURE - The present invention provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The present invention also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The present invention further provides a method of using the nutritional supplement for treating patients with heart failure. | 2015-08-27 |
20150238465 | NOVEL, PROTECTIVE, ANTI-INFLAMMATORY RECEPTOR AND ITS USE IN PRESERVATION OF MITOCHONDRIAL FUNCTION, WOUND HEALING AND REPAIR - Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT | 2015-08-27 |
20150238466 | LIM KINASE INHIBITORS - The invention relates to compounds for reducing or inhibiting a biological function mediated by LIMK1 or LIMK2, wherein the compounds are selected to bind the ATP-binding site and/or the substrate-binding site of LIMK. | 2015-08-27 |
20150238467 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - This invention relates to pharmaceutical compositions comprising 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (C1100), to processes for preparing the compositions, and to various therapeutic uses of the combinations. Also provided is a method of treatment of Duchenne muscular dystrophy or Becker muscular dystrophy using the compositions. | 2015-08-27 |
20150238468 | THIAZOLE DERIVATIVES FOR TREATING DYSKINESIAS CAUSED BY A CHEMICAL TREATMENT - The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment. | 2015-08-27 |
20150238469 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. | 2015-08-27 |
20150238470 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Methods of using Muscarinic Acetylcholine Receptor Antagonists are provided. | 2015-08-27 |
20150238471 | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS - A method or composition including 6-aminopyridin-3-ol derivatives or pharmaceutically acceptable salts thereof for treating a disease caused by angiogenesis, the 6-aminopyridin-3-ol derivatives represented by Formula 1 or the pharmaceutically acceptable salts thereof have excellent neoangiogenesis inhibition effects in the chorioallantoic membrane model, and are suitable for use as a drug for the treatment of disease caused by angiogenesis. | 2015-08-27 |
20150238472 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof - The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X. | 2015-08-27 |
20150238473 | METHODS AND COMPOSITIONS FOR TREATING INFECTION - Provided herein are compositions and methods for treating or preventing infection. | 2015-08-27 |
20150238474 | Methods for Treatment of Fabry Disease - Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. | 2015-08-27 |
20150238475 | INHIBITION OF QUORUM SENSING-MEDIATED PROCESSES IN BACTERIA - Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production. | 2015-08-27 |
20150238476 | PAYLOAD MOLECULE DELIVERY USING MOLECULAR REBAR - In various embodiments a payload molecule or drug molecule delivery system is disclosed. The system comprises a plurality of functionalized discrete carbon nanotubes having specific properties. The composition can comprise a plurality of discrete carbon nanotubes that have at least a portion of the carbon nanotubes with a number average (ratio of number average contour length to end to end length) of greater than 1.1 and up to about 3. These discrete carbon nanotubes having the specified ratio of number average (tube contour length (T | 2015-08-27 |
20150238477 | Method of Treating Lung Adenocarcinoma - This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with KIF5B-RET fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGF, and RET which is a compound of Formula I: | 2015-08-27 |
20150238478 | PPAR GAMMA AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS - Methods of treatment of multiple sclerosis (MS) with PPARγ agonists, and in particular with the compound of formula (I) known as INT | 2015-08-27 |
20150238479 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders - The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition: | 2015-08-27 |
20150238480 | QUINOLINONE DERIVATIVES - The present invention relates to compounds of the formula (I), | 2015-08-27 |
20150238481 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-08-27 |
20150238483 | Traitement des neuronopathies motrices - The invention relates to a calcium channel blocker selected from the group of the calcium channel blockers of the phenylalkylamine family, the calcium channel blockers of the amino acid family, and the calcium channel blockers of the benzofuran family, for the use thereof in the treatment of a motor neuronopathy. | 2015-08-27 |
20150238485 | OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS - The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): | 2015-08-27 |
20150238486 | NOVEL USES - This invention relates to the new use of the compound (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of pruritus and to combinations for such a use. | 2015-08-27 |
20150238487 | NOVEL ERGOLINE DERIVATIVES AND USES THEREOF - Provided herein are 8′-Hydroxy-2-CF3-dihydroergotamine (8′OH-2-CF3-DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2015-08-27 |
20150238488 | DRUG COMPOSITION FOR TREATING TUMORS AND APPLICATION THEREOF - The present invention belongs to the field of medicine and pharmaceutical chemistry, specifically relates to novel antitumor pharmaceutical combinations, and particularly relates to pharmaceutical combinations of bisbenzylisoquinoline alkaloids (e.g. berbamine and tetrandrine) and imatinib mesylates and their use in treating tumors. | 2015-08-27 |
20150238489 | HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES - Methods, uses, medicaments, and unit doses for treating viral diseases are described herein. The methods, uses, medicaments, and unit doses include (a) substituted piperidine and piperazine carboxamides, or a pharmaceutically acceptable salt thereof and (b) one or more pharmaceutically acceptable carriers, excipients or diluents, or combinations thereof. Viral diseases include hepatitis C virus, HIV, BVDV, and Coronavirus infections. | 2015-08-27 |
20150238490 | BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH IBRUTINIB - Described herein are diagnostic methods for selecting patients diagnosed with diffuse large B-cell lymphoma (DLBCL) for treatment with an inhibitor of Bruton's tyrosine kinase (BTK) based on the level of expression the biomarkers CCL3 and/or CCL4. Also provided are methods for identifying DLBCL patients likely to respond to treatment with a BTK inhibitor and for evaluating treatment of DLBCL with a BTK inhibitor. Methods of treating a patient also are provided. Also provided are compositions, combinations, and kits. | 2015-08-27 |
20150238491 | Modulators of Androgen Synthesis - The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds. | 2015-08-27 |
20150238492 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2015-08-27 |